The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)

María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, Alma Keco-Huerga, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Dino Vaira, Luis Fernández-Salazar, Jose M. Huguet, Jorge Pérez-Lasala, Natasa Brglez Jurecic, Galina Fadeenko, Jesús Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Marcis Leja, Javier Molina-Infante, Pavel BogomolovSergey Alekseenko, Manuel Domínguez-Cajal, Judith Gómez-Camarero, Vassiliki Ntouli, Samuel J. Martínez-Domínguez, Rafael Ruiz-Zorrilla, Oscar Núñez, Aiman Silkanovna Sarsenbaeva, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert*, Hp-EuReg Investigators

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
3 Downloads (Pure)


Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Original languageEnglish
Article number965
Number of pages22
Issue number8
Early online date11 Aug 2021
Publication statusPublished - 11 Aug 2021

Bibliographical note

Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG), and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).

Data Availability Statement

The data presented in this study are available on request from the corresponding author.
Supplementary Materials are available online at


  • Helicobacter pylori
  • Statins
  • Treatment


Dive into the research topics of 'The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)'. Together they form a unique fingerprint.

Cite this